(Albany, United States) As per DelveInsight’s assessment, globally, the Knee osteoarthritis pipeline constitutes 40+ key companies continuously working towards developing 40+ Knee osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Knee osteoarthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Knee osteoarthritis NDA approvals (if any), and product development activities comprising the technology, Knee osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Knee osteoarthritis pipeline treatment landscape of the report, click here @ Knee osteoarthritis Pipeline Outlook

 

Key Takeaways from the Knee osteoarthritis Pipeline Report

• DelveInsight’s Knee osteoarthritis Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
• The leading Knee osteoarthritis Companies working in the market include Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co. Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, and others
• Promising Knee osteoarthritis Pipeline Therapies in the various stages of development include Lorecivivint, JTA-004, Triamcinolone Injection, Cosamin DS®1% Diclofenac Topical Gel, GXCPC1, PK101, DFV890, CNTX-4975-05, Qutenza, and others.
• On March 2023, Organogenesis announced a study of phase 3 clinical trials for Amniotic Suspension Allograft. This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
• On June 2023, Biosplice Therapeutics Inc announced a study of phase 3 clinical trials for Lorecivivint.This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize standard outcomes to evaluate the safety and efficacy of lorecivivint.
• On March 2023, Medipost Co Ltd announced a study of phase 2 clinical trials for SMUP-IA-01(low dose). This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee – i.e., the more severely affected knee), and enroll in this study.

 

Knee osteoarthritis Overview

Knee osteoarthritis is defined by degeneration of the knee’s articular cartilage—the flexible, slippery material that normally protects bones from joint friction and impact. The condition also involves changes to the bone underneath the cartilage and can affect nearby soft tissues.

 

To explore more information on the latest breakthroughs in the Knee osteoarthritis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

 

Knee osteoarthritis Emerging Drugs Profile

• JTA-004: Bone Therapeutics
• MM-II: Moebius Medical

 

Knee osteoarthritis Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Knee osteoarthritis. The Knee osteoarthritis companies which have their Knee osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Bone Therapeutics.

 

Request a sample and discover the recent advances in Knee osteoarthritis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

 

Knee osteoarthritis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Knee osteoarthritis Therapeutics Market include-

Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co. Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, and others.

 

Dive deep into rich insights for drugs for Knee osteoarthritis Pipeline, click here for Knee osteoarthritis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

 

Scope of the Knee osteoarthritis Pipeline Report

• Coverage- Global
• Knee osteoarthritis Companies- Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co. Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, and others.
• Knee osteoarthritis Pipeline Therapies- Lorecivivint, JTA-004, Triamcinolone Injection, Cosamin DS®1% Diclofenac Topical Gel, GXCPC1, PK101, DFV890, CNTX-4975-05, Qutenza, and others.
• Knee osteoarthritis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Knee osteoarthritis Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Knee osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Knee osteoarthritis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. JTA-004: Bone Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MM-II: Moebius Medical
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PPV-06: Peptinov
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Knee osteoarthritis Key Companies
21. Knee osteoarthritis Key Products
22. Knee osteoarthritis- Unmet Needs
23. Knee osteoarthritis- Market Drivers and Barriers
24. Knee osteoarthritis- Future Perspectives and Conclusion
25. Knee osteoarthritis Analyst Views
26. Knee osteoarthritis Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services